The estimated Net Worth of J Michael Md Lazarus is at least $269 Thousand dollars as of 15 December 2005. J Lazarus owns over 10,000 units of Novavax stock worth over $269,483 and over the last 23 years J sold NVAX stock worth over $0.
J has made over 2 trades of the Novavax stock since 2001, according to the Form 4 filled with the SEC. Most recently J exercised 10,000 units of NVAX stock worth $37,500 on 15 December 2005.
The largest trade J's ever made was exercising 10,000 units of Novavax stock on 15 December 2005 worth over $37,500. On average, J trades about 2,385 units every 315 days since 2001. As of 15 December 2005 J still owns at least 21,927 units of Novavax stock.
You can see the complete history of J Lazarus stock trades at the bottom of the page.
J's mailing address filed with the SEC is 60 OLD COLONY RD, , WELLESLEY HILLS, MA, 02481.
Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi, and Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax executives and other stock owners filed with the SEC include: